ENDORSEMENT FROM EUROPEAN PROFESSIONAL SOCIETIES

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society: EUEYE
www.eueye.org

Signature

Professor Carlo E. Traverso - President



EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
ESCRS	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
European Association for Diabetic Eye Complications (EAsDEC)	 Tunde Peto EAsDEC President

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
AUSTRIAN SOCIETY OF OPHTHALMOLOGY	DR. KATHARINA KREPLER

BEAVRS

British & Eire Association of Vitreoretinal Surgeons

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology society:

Name of Society

BRITISH AND EIRE ASSOCIATION OF VITREORETINAL SURGEONS____

President: Mr Stephen Charles

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
CZECH VITREORETINAL SOCIETY	10/AUG/2023

Česká vitreoretinální společnost, z.s.
U vojenské nemocnice 1200
169 02 Praha 6
IČ: 70857635
DIČ: CZ70857636

MUDr. Pavel Němec

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Dutch vitreoretinal society	
J. de Hoog, president, ophthalmologist	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Estonian Society of Ophthalmology	
Estonian Society of Ophthalmic Surgeons	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Berlin Brandenburgische Augenärztliche Gesellschaft BBAG	Prof Dr. A. Jonssen
www.bbag-augen.de	Prof. Dr. med. Oliver Zeitz Facharzt für Augenheilkunde

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
DGII (German Society of Cataract & Refractive Surgery)	(President)

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
DIE AUGENCHIRURGINNEN **Die Augenchirurginnen e.V.** Vorstand: Prof. Dr. A. Liekfeld (Vorsitz), Dr. R. Bölöni, Priv-Doz. Dr. V. Brücher, Dr. A. Brusis, Dr. A. Frimpong-Boateng, Priv.-Doz. Dr. C. Jandeck, Priv.-Doz. Dr. A. Reisinger Website: www.augenchirurginnen.de E-Mail: kontakt@augenchirurginnen.de	(Liekfeld)

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
German Retinological Society	Prof. Dr. med. Nicolas Feltgen Oberarzt

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Greek Vitreoretinal Society	S. PAROIKAKIS President of the Board

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
IOIS - International Ocular Inflammation Society	Prof. Dr. Bahram Bodaghi - IOIS President

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
FLORETINA	Stanislao Rizzo

ROME - ITALY

6th of AUGUST 2023

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
ITALIAN GROUP OF VITREO RETINAL SURGERY (GIVRE)	(PRESIDENT GIVRE)

S.I.S.O.
Società Italiana di Scienze
Oftalmologiche
Ente del Terzo Settore
siso.ets@gmail.com

Rome, 3*rd* August 2023

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.

Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society

SISO

(Società Italiana di Scienze Oftalmologiche)

Signature

Teresio Avitabile

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
LITHUANIAN OPHTHALMOLOGY SOCIETY	PRESIDENT PROF. V. J. BALČIŪNIENĖ

Lietuvos akių gydytojų draugija
KAUNAS

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Polish Society Of Ophthalmology -	Professor Jerzy Mackiewicz 14/Aug/2023

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Sociedade Portuguesa de Oftalmologia (Portuguese Ophthalmology Society)	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society

Société Française d'Ophtalmologie

Carl ARNDT (President)

Signature

Carl Arndt (President)

INDIVIDUAL ENDORSEMENTS

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Klinikum Ernst-von Bergmann	A. Goebel Risk
	10.8.2023

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
German Retina Society & EURETINA	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Retinologische Gesellschaft Germany	Dr. med. Georg Fischer-Varvitsiotis Rolander Weg 30 40629 Düsseldorf



EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
DOG ESCRS	
Zaccigo, Rachel	
Sheh, Yumit Ismail	
STEIN, TOBIAS	
ESCRS / DOG	
Türkmen Öykü	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
German Retina Society	Klaus Lemmen, MD K. Lemmen

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Pallas Klinik
PD Dr. med. A. Weinberger
Louis Giroud-Strasse 20
4600 Olten

Name of the society	Signature
Retinologische Gesellschaft	Andreas Weinberger

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Klinikum Ernst von Bergmann gGmbH Klinik für Augenheilkunde Chefärztin Prof. Dr. med. habil. Anja Liekfeld, FEBO Charlottenstraße 72, 14467 Potsdam Tel. (0331) 241 3 5101, Fax (0331) 241 3 5110	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Retinological Society (RG) – Germany –	Dr. med. Christian K. Brinkmann Chefarzt Klinik für Augenheilkunde Dr. Christian Brinkmann, Netzhautchirurg.

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
German Retina Society / Dr. Claudia Dahlke	Zentrum für Augenheilkunde UNIKLINIK KÖLN Dr. med. Claudia Dahlke Oberärztin Tel. (0221) 478-4313

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Dr. med. Claudia Jochmann Oberärztin Universitätsklinikum Leipzig Department für Kopf- und Zahnmedizin Liebigstraße 10-14, Haus 1 · 04103 Leipzig Telefon 0341/97-21546	07.08.23

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Gerasimos Anastassiou, MD, PhD	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Retinal Society Germany Retinologische Gesellschaft (RG)	Düsseldorf, 4th Aug. 2023
Prof. Dr. med. Gernot Rößler Chefarzt Augenheilkunde St. Martinus-Krankenhaus Gladbacher Str. 26 • 40219 Düsseldorf	J. Rö

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
RG Deutschland	Ralf Krott

27 04 436
Priv. Doz. Dr. med. Ralf Krott
Dr. med. Frauke Sulimma
Fachärzte für Augenheilkunde
Hauptstr. 89
50996 Köln

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Olga Furashova (German Retina Society)	O Furashova

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Dr. Wilko Friedrichs Charlottenklinik für Augenheilkunde Stuttgart	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Klinikum Bremen Mitte	Meyer
Klinikum Bremen Mitte	N. Demircioglu Assistenzarzt

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Nessrin Krainau Klinikum Bremen-Mitte (Bremen, Germany)	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
RG DOG Euretina ARVO SFO	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

As member of following societies (beyond others)	Signature
Euretina, German Retina Society	
German and Swiss Ophthalmological Societies	
_____	_____
_____	_____
	_____

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
	Carsten Framme
DOG / RG Germany	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
German Retinologic Society - German ophthalmologic Society	7.8.2023 Prof. Dr. med. H. Hoerauf Direktor der Abt. f. Augenheilkunde Georg-August-Universität Göttingen Robert-Koch-Str. 40, 37075 Göttingen

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
SLK-Kliniken Heilbronn GmbH Klinikum am Gesundbrunnen Augenklinik Klinikdirektor Prof. Dr. med. L. Hesse 74078 Heilbronn Tel. 07131 / 4931001 · Fax 4731001	

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Vivantes Health Network Ltd. Neukölln Hospital Department of Ophthalmology Rudower Straße 48 12351 Berlin	Prof. Dr. Sabine Aisenbrey, FEBO

EURETINA presented a comment on the "European Commission staff working document on Poly- and perfluoroalkyl substances (PFAS)". The aim is to highlight and motivate the irreplaceability of the PFAS currently used in vitreoretinal surgery, namely hexafluoroethane (C2F6), octafluoropropane (C3F8), perfluoro-octane (PFO) and perfluodecalin (PFD), perfluorobutylpentane (F4H5), perfluorohexyloctane (F6H8), and heavy silicone oils (HSO). It is clearly stated that a ban of these compounds will result in an unmet clinical need due to the absence of effective alternative allowing the same quality of care.
Aware of the severity of the issues associated with PFAS, multiple initiatives will be taken to optimize their clinical use as well as disposal, and promote researches on alternative tamponade agents.

The content of the comment for Annex XV restriction report, presented by EURETINA, is entirely and strongly endorsed by the following ophthalmology societies:

Name of the society	Signature
Member of Retinologe. Gesellschaft	(Prof. Dr. Maya Hulla)
" " DOG	
" " AAO